PDF(Pubmed)
Abstract：
UNASSIGNED: The occurrence of partial remission (honeymoon phase) in type 1 diabetes (T1D) has been associated with a reduced risk of chronic microvascular complications of diabetes. We have published case reports showing that a combination therapy with the DPP-4 inhibitor sitagliptin plus vitamin D3 (VIDPP-4i) can prolong the honeymoon phase in patients with new-onset T1D. In the present case-control study, we investigated the frequency of occurrence of clinical remission (CR) in patients with new-onset T1D after VIDPP-4i treatment.
UNASSIGNED: In this case-control study, we collected data spanning 10 years from medical records of 46 patients (23 females) recently diagnosed with T1D. Overall, 27 participants with CR (insulin dose-adjusted glycated hemoglobin [IDAA1c] ≤ 9) at 12 or 24 months composed the case group, and 19 participants without CR served as the control group. Chi-square with Yates correction was used to analyze the association between VIDPP-4i use and CR, and odds ratio (OR) was used to determine the chance of CR due to VIDPP-4i treatment exposure.
UNASSIGNED: In all, 37 patients (80.4%) experienced CR at some time over 24 months. The mean CR duration was 13.15 ± 9.91 months. Treatment with VIDPP-4i was significantly associated with CR. At 24 months, the OR of CR after VIDPP-4i exposure was 9.0 (95% confidence interval [CI] 2.21-30.18, p = 0.0036). Additionally, 9 (33.6%) and 4 (14.8%) patients in the VIDPP-4i group experienced insulin-free CR at 12 and 24 months, respectively.
UNASSIGNED: Therapy with VIDPP-4i was associated with a higher frequency and duration of the honeymoon phase. Randomized controlled trials are needed to confirm these findings.
UNASSIGNED: In this case-control study, we collected data spanning 10 years from medical records of 46 patients (23 females) recently diagnosed with T1D. Overall, 27 participants with CR (insulin dose-adjusted glycated hemoglobin [IDAA1c] ≤ 9) at 12 or 24 months composed the case group, and 19 participants without CR served as the control group. Chi-square with Yates correction was used to analyze the association between VIDPP-4i use and CR, and odds ratio (OR) was used to determine the chance of CR due to VIDPP-4i treatment exposure.
UNASSIGNED: In all, 37 patients (80.4%) experienced CR at some time over 24 months. The mean CR duration was 13.15 ± 9.91 months. Treatment with VIDPP-4i was significantly associated with CR. At 24 months, the OR of CR after VIDPP-4i exposure was 9.0 (95% confidence interval [CI] 2.21-30.18, p = 0.0036). Additionally, 9 (33.6%) and 4 (14.8%) patients in the VIDPP-4i group experienced insulin-free CR at 12 and 24 months, respectively.
UNASSIGNED: Therapy with VIDPP-4i was associated with a higher frequency and duration of the honeymoon phase. Randomized controlled trials are needed to confirm these findings.
摘要：
■1型糖尿病（T1D）中部分缓解（蜜月期）的发生与糖尿病慢性微血管并发症的风险降低有关。我们已发表的病例报告显示，与DPP-4抑制剂西格列汀加维生素D3（VIDPP-4i）联合治疗可延长新发T1D患者的蜜月期。在本病例对照研究中，我们调查了VIDPP-4i治疗后新发T1D患者临床缓解(CR)的发生频率.
■在本病例对照研究中，我们从最近诊断为T1D的46例患者(23例女性)的医疗记录中收集了10年的数据.总的来说,病例组27名12个月或24个月时CR（胰岛素剂量调整糖化血红蛋白[IDA1c]≤9）的参与者，19名无CR的参与者作为对照组。用Yates校正的卡方法分析VIDPP-4i使用与CR之间的关联，和比值比（OR）用于确定由于VIDPP-4i治疗暴露而导致CR的机会。
■总之，37名患者（80.4%）在24个月内的某个时间经历了CR。平均CR持续时间为13.15±9.91个月。VIDPP-4i治疗与CR显著相关。24个月时,VIDPP-4i暴露后CR的OR为9.0（95％置信区间[CI]2.21-30.18，p=0.0036）。此外,VIDPP-4i组中有9例（33.6％）和4例（14.8％）患者在12和24个月时出现无胰岛素CR，分别。
■VIDPP-4i治疗与蜜月期的更高频率和持续时间相关。需要随机对照试验来证实这些发现。
■在本病例对照研究中，我们从最近诊断为T1D的46例患者(23例女性)的医疗记录中收集了10年的数据.总的来说,病例组27名12个月或24个月时CR（胰岛素剂量调整糖化血红蛋白[IDA1c]≤9）的参与者，19名无CR的参与者作为对照组。用Yates校正的卡方法分析VIDPP-4i使用与CR之间的关联，和比值比（OR）用于确定由于VIDPP-4i治疗暴露而导致CR的机会。
■总之，37名患者（80.4%）在24个月内的某个时间经历了CR。平均CR持续时间为13.15±9.91个月。VIDPP-4i治疗与CR显著相关。24个月时,VIDPP-4i暴露后CR的OR为9.0（95％置信区间[CI]2.21-30.18，p=0.0036）。此外,VIDPP-4i组中有9例（33.6％）和4例（14.8％）患者在12和24个月时出现无胰岛素CR，分别。
■VIDPP-4i治疗与蜜月期的更高频率和持续时间相关。需要随机对照试验来证实这些发现。
